NXC 828
Alternative Names: NXC-828Latest Information Update: 29 Nov 2022
Price :
$50 *
At a glance
- Originator NextGen Bioscience
- Class Eye disorder therapies; Small molecules
- Mechanism of Action Hypoxia-inducible factor 1 alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Wet age-related macular degeneration
Most Recent Events
- 23 Nov 2022 NextGen Bioscience plans a phase I/II trial for Wet age-related macular degeneration in in 2Q of 2023 (Ophthalmic, Drops)
- 23 Nov 2022 NXC 828 is available for licensing as of 23 Nov 2022. http://www.nextgenbio.co.kr/skin/page/contact01_en.html
- 23 Nov 2022 Preclinical trials in Wet age-related macular degeneration in South Korea (Ophthalmic) (NextGen Bioscience pipeline, November 2022)